Automation surge in the manufacturing of High Potency Medicines

High potency medicines are therapeutic products which provide treatment even with a low amount of dose. The production of these drugs involves utilization of significantly potent ingredients that require extra-thorough care during the supply chain/production. Many of the pharmaceutical companies have started increasing the development of high potency medicines which has been caused by an increasing prevalence of chronic/life-threatening diseases resulting in transformation of the pharmaceutical manufacturing methods. The production of high potency medicines involves having to provide extra precautionary measures while the drug is under development as it utilizes highly potent ingredients requiring specialized manufacturing equipments in an isolated facility. Major pharmaceutical companies have stepped up their research & development activities, as they provide valuable information regarding the efficacy of these ingredients, which can then be used to classify their potency helping limit the exposure levels accordingly. The number of pharmaceuticals currently under development which are highly potent stands at around 80-90% of the total quantity. On the rising quantity of highly potent medicines, various pharmaceutical equipment manufacturers have taken this opportunity to develop specialized machinery to promote efficiency of the supply chain while limiting the exposure of these ingredients to humans at an even declined level. Also, due to the reduced dosage requirements the packaging has to be of a very specific nature therefore requiring an automated packaging process, as it results in lower chances of human error and provides better flexibility to the complete supply chain. With the advancements in technology and information regarding the methods required for the development of high potency medicines, the equipment manufacturers have taken this need as a cue to develop innovative equipments for the pharmaceutical industry. Currently, the innovations available with the machinery are associated with limiting the interaction between humans and the highly potent active pharmaceutical ingredient (HPAPI), which has resulted in availability of robotic arms during the interaction of small molecules while the research activities are underway. The significant surge of Industry 4.0 is also one of the major technological trends currently prevalent with the development of high potency medicines, as it essentially means that the equipments are equipped enough to overcome and fulfil even the most complicated processes, such as an all-in-one supply chain solution which can provide manufacturing, filling the contents in the package and completing the packaging of these medicines, for the most diverse quantity requirements. These equipments are also being integrated with digitization age which essentially means that the supply chain can be operated under a single operating system even if the supply chain consists of machinery from different suppliers. However, this requires the development of machinery capable of being integrated with the digitization and operating in collaboration with other equipments. For the achievement of complete automation, a number of pharmaceutical service providers have started providing specialized offerings where they integrate the machinery for the pharmaceutical manufacturers and provide the information regarding the effectiveness and efficacy of this integration. To round off, many of the pharmaceutical manufacturers have identified their requirements and are outlining them to the equipment manufacturers. On top of it, many of the equipment manufacturers have started providing testing of facilities which provides invaluable information whether the facility is equipped enough to handle the continuous production of high potency medicines.